1.2% rosuvastatin gel as a local drug delivery agent in smokers with chronic periodontitis – A randomized controlled clinical trial

Background: Etiological factors for periodontal diseases are multifactorial and one of these etiologic agents is bacteria. Mechanical therapy itself may not eliminate the anaerobic infection at the base of the pocket. To overcome this, various drug delivered locally have been used in adjunct to scaling and root planing (SRP). The present trial aims to evaluate the efficacy of 1.2% rosuvastatin (RSV) gel locally delivered as an adjunct to SRP in smokers with chronic periodontitis (CP). Materials and Methods: A total of 60 patients were randomly divided into two treatment groups: SRP with plac-ebo gel (Group 1) and SRP with 1.2% RSV gel (Group 2). Clinical parameters were evaluated at baseline, 3, 6, and 9 months. Radioic assessment was done at baseline and 6 and 9 months using computer-aided software. Results: As compared to placebo group, a significant greater mean probing depth reduction and greater mean gain in clinical attachment level were seen in the RSV group at different time periods. Moreover, a greater mean defect depth reduction was found in the RSV group (23.91 ± 1.03, 29.24 ± 0.834) after 6 and 9 months, respectively. Conclusion: Smokers with CP patients showed significant improvement in evaluated clinical parameters in RSV group with greater percentage of defect depth reduction as compared to placebo group.